Rapid frozen section immunostaining of melanocytes by microphthalmia- associated transcription factor

American Journal of Dermatopathology

Volumn 32, Issue 4, 2010, Pages 319-325

  Glass, L Frank ^a,b,c   Raziano, Renata M ^a   Clark, Graham S ^c   Higgins, H William ^d   Ladd, Sharron ^a   Lien, Mary H ^a,c   Chen, Ren ^e   Cherpelis, Basil S ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d FLORIDA STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Frozen sections; Immunohistochemistry; Melanocytes; Melanoma; Mohs surgery

Indexed keywords

DIAMINOBENZIDINE; MELAN A; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR;

ARTICLE; CELL DENSITY; CHEMOSURGERY; CLINICAL PROTOCOL; CONTROLLED STUDY; ELECTRON MICROSCOPY; FROZEN SECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOCYTE; MELANOMA; NUCLEAR SIZE; PRIORITY JOURNAL; RELIABILITY;

ANTIGENS, NEOPLASM; FROZEN SECTIONS; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOCYTES; MELANOMA; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; MOHS SURGERY; NEOPLASM PROTEINS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77952929989     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/DAD.0b013e3181bcd94f     Document Type: Article

References (57)

1. Bricca GM, Brodland DG, Ren D, et al. Cutaneous head and neck melanoma treated with Mohs micrographic surgery. J Am Acad Dermatol. 2005;52:92-100.
2. Huilgol SC, Selva D, Chen C, et al. Surgical margins for lentigo maligna and lentigo maligna melanoma: the technique of mapped serial excision. Arch Dermatol. 2004;140:1087-1092.
3. Albertini JG, Elston DM, Libow LF, et al. Mohs micrographic surgery for melanoma: a case series, a comparative study of immunostains, an informative case report, and a unique mapping technique. Dermatol Surg. 2002;28:656-665.
4. Zalla MJ, Lim KK, Dicaudo DJ, et al. Mohs micrographic excision of melanoma using immunostains. Dermatol Surg. 2000;26:771-784.
5. Agarwal-Antal N, Bowen GM, Gerwels JW. Histologic evaluation of lentigo maligna with permanent sections: implications regarding current guidelines. J Am Acad Dermatol. 2002;47:743-748.
6. Moller MG, Pappas-Politis E, Zager JS, et al. Surgical management of melanoma-in-situ using a staged marginal and central excision technique. Ann Surg Oncol. 2009;16:1526-1536.
7. Zitelli JA, Brown CD, Hanusa BH. Surgical margins for excision of primary cutaneous melanoma. J Am Acad Dermatol. 1997;37:422-429.
8. Bub JL, Berg D, Slee A, et al. Management of lentigo maligna and lentigo maligna melanoma with staged excision: a 5-year follow-up. Arch Dermatol. 2004;140:552-558.
9. Walling HW, Scupham RK, Bean AK, et al. Staged excision versus Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol. 2007;57:659-664.
10. Temple CL, Arlette JP. Mohs micrographic surgery in the treatment of lentigo maligna and melanoma. J Surg Oncol. 2006;94:287-292.
11. Bhardwaj SS, Tope WD, Lee PK. Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma using Mel-5 immunostaining: University of Minnesota experience. Dermatol Surg. 2006;32:690-696; discussion 696-697.
12. Bienert TN, Trotter MJ, Arlette JP. Treatment of cutaneous melanoma of the face by Mohs micrographic surgery. J Cutan Med Surg. 2003;7:25-30.
13. Bene NI, Healy C, Coldiron BM. Mohs micrographic surgery is accurate 95.1% of the time for melanoma in situ: a prospective study of 167 cases. Dermatol Surg. 2008;34:660-664.
14. Kelley LC, Starkus L. Immunohistochemical staining of lentigo maligna during Mohs micrographic surgery using MART-1. J Am Acad Dermatol. 2002;46:78-84.
15. Stranahan D, Cherpelis BS, Glass LF, et al. Immunohistochemical stains in Mohs surgery: a review. Dermatol Surg. 2009;35:1023-1034.
16. Thosani MK, Marghoob A, Chen CS. Current progress of immunostains in Mohs micrographic surgery: a review. Dermatol Surg. 2008;34:1621-1636.
17. Dawn ME, Dawn AG, Miller SJ. Mohs surgery for the treatment of melanoma in situ: a review. Dermatol Surg. 2007;33:395-402.
18. Davis DA, Kurtz KA, Robinson RA. Ultrarapid staining for cutaneous melanoma: study and protocol. Dermatol Surg. 2005;31:753-756; discussion 756.
19. El Shabrawi-Caelen L, Kerl H, Cerroni L. Melan-A: not a helpful marker in distinction between melanoma in situ on sun-damaged skin and pigmented actinic keratosis. Am J Dermatopathol. 2004;26:364-366.
20. Beltraminelli H, Shabrawi-Caelen LE, Kerl H, et al. Melan-a-positive "pseudomelanocytic nests": a pitfall in the histopathologic and immunohistochemical diagnosis of pigmented lesions on sun-damaged skin. Am J Dermatopathol. 2009;31:305-308.
21. Maize JC Jr, Resneck JS Jr, Shapiro PE, et al. Ducking stray "magic bullets": a Melan-A alert. Am J Dermatopathol. 2003;25:162-165.
22. Miettinen M, Fernandez M, Franssila K, et al. Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers. Am J Surg Pathol. 2001;25:205-211.
23. Granter SR, Weilbaecher KN, Quigley C, et al. Role for microphthalmia transcription factor in the diagnosis of metastatic malignant melanoma. Appl Immunohistochem Mol Morphol. 2002;10:47-51.
24. King R, Googe PB, Weilbaecher KN, et al. Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors. Am J Surg Pathol. 2001;25:51-57.
25. King R, Weilbaecher KN, McGill G, et al. Microphthalmia transcription factor: a sensitive and specific melanocyte marker for melanoma diagnosis. Am J Pathol. 1999;155:731-738.
26. Busam KJ, Iversen K, Coplan KC, et al. Analysis of microphthalmia transcription factor expression in normal tissues and tumors, and comparison of its expression with S-100 protein, gp100, and tyrosinase in desmoplastic malignant melanoma. Am J Surg Pathol. 2001;25:197-204.
27. Busam KJ, Kucukgol D, Sato E, et al. Immunohistochemical analysis of novel monoclonal antibody PNL2 and comparison with other melanocyte differentiation markers. Am J Surg Pathol. 2005;29:400-406.
28. Hemesath TJ, Steingrimsson E, McGill G, et al. Microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family. Genes Dev. 1994;8:2770-2780.
29. Yasumoto K, Yokoyama K, Shibata K, et al. Microphthalmia-associated transcription factor as a regulator for melanocyte-specific transcription of the human tyrosinase gene. Mol Cell Biol. 1994;14:8058-8070.
30. Bentley NJ, Eisen T, Goding CR. Melanocyte-specific expression of the human tyrosinase promoter: activation by the microphthalmia gene product and role of the initiator. Mol Cell Biol. 1994;14:7996-8006.
31. McGill GG, Horstmann M, Widlund HR, et al. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell. 2002;109:707-718.
32. Bertolotto C, Abbe P, Hemesath TJ, et al. Microphthalmia gene product as a signal transducer in cAMP-induced differentiation of melanocytes. J Cell Biol. 1998;142:827-835.
33. Price ER, Horstmann MA, Wells AG, et al. alpha-Melanocyte-stimulating hormone signaling regulates expression of microphthalmia, a gene deficient in Waardenburg syndrome. J Biol Chem. 1998;273:33042-33047.
34. Hemesath TJ, Price ER, Takemoto C, et al. MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature. 1998;391:298-301.
35. Cherpelis BS, Moore R, Ladd S, et al. Comparison of MART-1 frozen sections to permanent sections using a rapid 19-minute protocol. Dermatol Surg. 2009;35:207-213.
36. Barlow JO, Maize J Sr., Lang PG. The density and distribution of melanocytes adjacent to melanoma and nonmelanoma skin cancers. Dermatol Surg. 2007;33:199-207.
37. Acker SM, Nicholson JH, Rust PF, et al. Morphometric discrimination of melanoma in situ of sun-damaged skin from chronically sun-damaged skin. J Am Acad Dermatol. 1998;39:239-245.
38. Hendi A, Brodland DG, Zitelli JA. Melanocytes in long-standing sun-exposed skin: quantitative analysis using the MART-1 immunostain. Arch Dermatol. 2006;142:871-876.
39. Weyers W, Bonczkowitz M, Weyers I, et al. Melanoma in situ versus melanocytic hyperplasia in sun-damaged skin. Assessment of the significance of histopathologic criteria for differential diagnosis. Am J Dermatopathol. 1996;18:560-566.
40. Toyoda M, Morohashi M. Morphological alterations of epidermal melanocytes in photoageing: an ultrastructural and cytomorphometric study. Br J Dermatol. 1998;139:444-452.
41. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Melanoma [Internet]. 2007. Available at: Http://www.nccn.org/ professionals/physician-gls/PDF/melanoma.pdf. Accessed September 1, 2007.
42. National Institutes of Health Consensus Development Conference Statement on Diagnosis and Treatment of Early Melanoma, January 27-29, 1992. Am J Dermatopathol. 1993;15:34-43; discussion 46-51.
43. Jejurikar SS, Borschel GH, Johnson TM, et al. Immediate, optimal reconstruction of facial lentigo maligna and melanoma following total peripheral margin control. Plast Reconstr Surg. 2007;120:1249-1255.
44. Mahoney MH, Joseph M, Temple CL. The perimeter technique for lentigo maligna: an alternative to Mohs micrographic surgery. J Surg Oncol. 2005;91:120-125.
45. Anderson KW, Baker SR, Lowe L, et al. Treatment of head and neck melanoma, lentigo maligna subtype: a practical surgical technique. Arch Facial Plast Surg. 2001;3:202-206.
46. Clayton BD, Leshin B, Hitchcock MG, et al. Utility of rush paraffin-embedded tangential sections in the management of cutaneous neoplasms. Dermatol Surg. 2000;26:671-678.
47. Cohen LM, McCall MW, Hodge SJ, et al. Successful treatment of lentigo maligna and lentigo maligna melanoma with Mohs' micrographic surgery aided by rush permanent sections. Cancer. 1994;73:2964-2970.
48. Cohen LM, McCall MW, Zax RH. Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma. A follow-up study. Dermatol Surg. 1998;24:673-677.
49. Johnson TM, Headington JT, Baker SR, et al. Usefulness of the staged excision for lentigo maligna and lentigo maligna melanoma: the "square" procedure. J Am Acad Dermatol. 1997;37:758-764.
50. Zitelli JA, Brown C, Hanusa BH. Mohs micrographic surgery for the treatment of primary cutaneous melanoma. J Am Acad Dermatol. 1997; 37:236-245.
51. Zitelli JA, Moy RL, Abell E. The reliability of frozen sections in the evaluation of surgical margins for melanoma. J Am Acad Dermatol. 1991; 24:102-106.
52. Barlow RJ, White CR, Swanson NA. Mohs' micrographic surgery using frozen sections alone may be unsuitable for detecting single atypical melanocytes at the margins of melanoma in situ. Br J Dermatol. 2002; 146:290-294.
53. Bricca GM, Brodland DG, Zitelli JA. Immunostaining melanoma frozen sections: the 1-hour protocol. Dermatol Surg. 2004;30:403-408.
54. Wiltz KL, Qureshi H, Patterson JW, et al. Immunostaining for MART-1 in the interpretation of problematic intra-epidermal pigmented lesions. J Cutan Pathol. 2007;34:601-605.
55. Helm K, Findeis-Hosey J. Immunohistochemistry of pigmented actinic keratoses, actinic keratoses, melanomas in situ and solar lentigines with Melan-A. J Cutan Pathol. 2008;35:931-934.
56. Florell SR, Boucher KM, Leachman SA, et al. Histopathologic recognition of involved margins of lentigo maligna excised by staged excision: an interobserver comparison study. Arch Dermatol. 2003;139: 595-604.
57. Blake B, Clark GS, Cherpelis BS, et al. Melanocyte density and nuclear size distinguishes melanoma in situ (MIS) from solar lentigo/lentiginous melanocytic hyperplasia (LMH). Am J Dermatopathol. 2009;31:411.